文献速递血脂与心血管预防冠心病

家族性高胆固醇血症在普通人群与动脉粥样硬化性心血管病患者中的患病率:系统综述与荟萃分析

Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.
PubMed 文献 · Circulation · 2020-05-29

该系统综述与荟萃分析纳入42项普通人群研究和20项ASCVD患者研究,估计杂合子家族性高胆固醇血症(FH)的汇总患病率在普通人群为1:311(95%CI 1:250-1:397),在ASCVD患者为1:17(95%CI 1:12-1:24),主要由冠心病驱动(1:16)。结果支持推行筛查等公共卫生政策以早期识别FH并预防其全球负担。

要点

  • 普通人群FH汇总患病率为1:311(95%CI 1:250-1:397)。
  • ASCVD患者FH患病率为普通人群的18倍(1:17,95%CI 1:12-1:24)。
  • 冠心病患者FH患病率为1:16(95%CI 1:12-1:23)。

核心结论

  • FH总体患病率为1:311,是普通人群中最常见的遗传性疾病之一,且在全球不同地区表现相似。
  • FH在ASCVD患者中更常见,ASCVD患者患病率为普通人群的18倍。
  • 结果支持倡导建立包括筛查项目在内的公共卫生政策,以早期识别FH并预防其全球负担。

研究设计与样本

  • 系统综述与荟萃分析,纳入报告普通人群或ASCVD患者中杂合子FH患病率的研究。
  • 排除报告基因奠基者效应及聚焦纯合子FH的研究。
  • 检索Medline、Embase、Cochrane和Global Health,无时间或语言限制。
  • 共纳入42项普通人群研究(7 297 363人/24 636例FH)和20项ASCVD患者研究(48 158例患者/2827例FH)。
  • 采用随机效应模型分别估计普通人群和ASCVD人群的汇总患病率,并按WHO区域分层;超过60%的研究来自欧洲,荷兰脂质临床网络标准是最常用诊断方法。

主要发现

  • 普通人群FH总体汇总患病率为1:311(95%CI 1:250-1:397)。
  • 儿童与成人患病率相似(1:364 vs 1:303,P=0.60);WHO各区域间(P=0.29)及人群为基础与电子健康记录为基础的研究间(P=0.82)无显著差异。
  • 样本量≤10 000的研究报告患病率更高(1:200-289),较大队列为1:365-407(P<0.001)。
  • ASCVD患者FH汇总患病率为1:17(95%CI 1:12-1:24),主要由冠心病驱动(1:16,95%CI 1:12-1:23)。
  • 研究间异质性大(I2>95%),偏倚检验无统计学意义(P>0.3)。

临床怎么用

  • 在ASCVD患者中应警惕FH,其患病率约为普通人群的18倍,尤其冠心病患者。
  • 可考虑对普通人群及ASCVD患者开展FH筛查以早期识别并启动预防。

局限性

  • 研究间异质性大(I2>95%)。
  • 超过60%的研究来自欧洲,其他区域数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contemporary studies suggest that familial hypercholesterolemia (FH) is more frequent than previously reported and increasingly recognized as affecting individuals of all ethnicities and across many regions of the world. Precise estimation of its global prevalence and prevalence across World Health Organization regions is needed to inform policies aiming at early detection and atherosclerotic cardiovascular disease (ASCVD) prevention. The present study aims to provide a comprehensive assessment and more reliable estimation of the prevalence of FH than hitherto possible in the general population (GP) and among patients with ASCVD. METHODS: We performed a systematic review and meta-analysis including studies reporting on the prevalence of heterozygous FH in the GP or among those with ASCVD. Studies reporting gene founder effects and focused on homozygous FH were excluded. The search was conducted through Medline, Embase, Cochrane, and Global Health, without time or language restrictions. A random-effects model was applied to estimate the overall pooled prevalence of FH in the general and ASCVD populations separately and by World Health Organization regions. RESULTS: From 3225 articles, 42 studies from the GP and 20 from populations with ASCVD were eligible, reporting on 7 297 363 individuals/24 636 cases of FH and 48 158 patients/2827 cases of FH, respectively. More than 60% of the studies were from Europe. Use of the Dutch Lipid Clinic Network criteria was the commonest diagnostic method. Within the GP, the overall pooled prevalence of FH was 1:311 (95% CI, 1:250-1:397; similar between children [1:364] and adults [1:303], P=0.60; across World Health Organization regions where data were available, P=0.29; and between population-based and electronic health records-based studies, P=0.82). Studies with ≤10 000 participants reported a higher prevalence (1:200-289) compared with larger cohorts (1:365-407; P<0.001). The pooled prevalence among those with ASCVD was 18-fold higher than in the GP (1:17 [95% CI, 1:12-1:24]), driven mainly by coronary artery disease (1:16; [95% CI, 1:12-1:23]). Between-study heterogeneity was large (I2>95%). Tests assessing bias were nonsignificant (P>0.3). CONCLUSIONS: With an overall prevalence of 1:311, FH is among the commonest genetic disorders in the GP, similarly present across different regions of the world, and is more frequent among those with ASCVD. The present results support the advocacy for the institution of public health policies, including screening programs, to identify FH early and to prevent its global burden.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Circulation. 2020. PMID: 32468833. doi:10.1161/CIRCULATIONAHA.119.044795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。